Patents by Inventor Hanlu WANG

Hanlu WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220288575
    Abstract: Disclosed is a method for preparing a carbonized silk photocatalyst, comprising; soaking a natural silk and an activator in water, taking out the soaked silk, and drying the same; and roasting the dried silk under the protection of an inert atmosphere to prepare a carbonized silk photocatalyst. Also disclosed is a method for photocatalytic desulfurization of a fuel oil, comprising: mixing a fuel oil to be desulfurated, an extraction agent and a carbonized silk photocatalyst, with air being used as an oxidizing agent, to conduct a photocatalytic reaction under light irradiation, and separating an upper oil phase to obtain a desulfurated fuel oil. The catalyst has a simple preparation process, and can effectively reduce dibenzothiophene sulfides, which are difficult to remove, in the fuel oil under UV light radiation. Desulfurization can be achieved at room temperature, and reaction conditions are mild.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 15, 2022
    Inventors: Xingye Zeng, Hanlu Wang, Shufeng Shan, Zhanjun Zhang, Shikui Wu, Rujin Zhou, Cunhui Lin
  • Patent number: 10351856
    Abstract: It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 16, 2019
    Assignee: BIOPHARMAGEN CORP., FANGZHOU SUZHOU
    Inventors: Hanlu Wang, Rihe Liu, Yongping Jiang
  • Publication number: 20190030174
    Abstract: It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.
    Type: Application
    Filed: March 23, 2017
    Publication date: January 31, 2019
    Inventors: Hanlu WANG, Rihe LIU, Yongping JIANG